Literature DB >> 25633506

A Single Center Experience Comparing Miniperc and Shockwave Lithotripsy for Treatment of Radiopaque 1-2 cm Lower Caliceal Renal Calculi in Children: A Prospective Randomized Study.

Anup Kumar1, Niraj Kumar1, Pawan Vasudeva1, Rohit Kumar1, Sanjeev Kumar Jha1, Harbinder Singh1.   

Abstract

BACKGROUND AND
PURPOSE: A prospective randomized study was performed comparing miniperc and shockwave lithotripsy (SWL) for treatment of radiopaque 1 to 2 cm lower caliceal renal calculi in children to evaluate safety and efficacy of these procedures. PATIENTS AND METHODS: Pediatric patients (<15 years) with a single radiopaque lower caliceal renal stone 1 to 2 cm undergoing treatment between March 2012 and September 2013 in our department were randomized into two groups-group A, miniperc; group B, SWL. The two groups were compared statistically regarding patient demographic profile, 3-month stone-free rate (SFR), re-treatment rates, auxiliary procedures, and complications.
RESULTS: There were 106 patients enrolled in each group. The mean age (10.3 years vs 10.7 years, P=0.57) and stone size (12.7 mm vs 12.9 mm, P=0.31) were similar between group A and B patients. The re-treatment rate and auxiliary procedure rate were significantly greater in group B compared with group A (41.5% vs 2.8% and 14.2% vs 5.6%, respectively; P<0.001). The overall 3-month SFR was 94.3% for group A vs 83% for group B (P=0.03). The complication rate (20.7% vs 3.7%; P=0.01) and hospital stay (3.7 days vs 7.1 hours; P=0.01) was significantly higher in group A compared with group B. Blood transfusion was given in 10.3% patients in group A vs none in group B (P=0.01).
CONCLUSIONS: Miniperc is more efficacious than SWL for treatment of radiopaque lower caliceal renal calculi 1 to 2 cm in children in terms of higher SFR and lesser auxiliary and re-treatment rates. Miniperc, however, resulted in more complication, operative time, radiation exposure, and hospital stay.

Entities:  

Mesh:

Year:  2015        PMID: 25633506     DOI: 10.1089/end.2015.0020

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  6 in total

Review 1.  Clinical effectiveness in the diagnosis and acute management of pediatric nephrolithiasis.

Authors:  Jason P Van Batavia; Gregory E Tasian
Journal:  Int J Surg       Date:  2016-11-14       Impact factor: 6.071

Review 2.  Reprint - Medical and surgical interventions for the treatment of urinary stones in children: A Cochrane Review.

Authors:  Lenka Barreto; Jae Hung Jung; Ameera Abdelrahim; Munir Ahmed; Guy P C Dawkins; Marcin Kazmierski
Journal:  Can Urol Assoc J       Date:  2019-10       Impact factor: 1.862

3.  What is the best approach for pediatric kidney stones of moderate-sized between shock wave lithotripsy, ultramini percutaneous nephrolithotomy and retrograde intrarenal surgery?

Authors:  Umut Unal; Mehmet Eflatun Deniz; Ferhat Ortoglu; Ediz Vuruskan; Hakan Anil; Adem Altunkol
Journal:  Pediatr Surg Int       Date:  2022-09-01       Impact factor: 2.003

4.  Is mini-percutaneous nephrolithotomy a safe alternative to extracorporeal shockwave lithotripsy in pediatric age group in borderline stones? a randomized prospective study.

Authors:  Ahmed Farouk; Ahmed Tawfick; Mohamed Shoeb; Mahmoud A Mahmoud; Diaa Eldin Mostafa; Mohamed Hasan; Hany M Abdalla
Journal:  World J Urol       Date:  2018-02-15       Impact factor: 4.226

Review 5.  Medical and surgical interventions for the treatment of urinary stones in children.

Authors:  Lenka Barreto; Jae Hung Jung; Ameera Abdelrahim; Munir Ahmed; Guy P C Dawkins; Marcin Kazmierski
Journal:  Cochrane Database Syst Rev       Date:  2018-06-02

6.  Which is the best treatment of pediatric upper urinary tract stones among extracorporeal shockwave lithotripsy, percutaneous nephrolithotomy and retrograde intrarenal surgery: a systematic review.

Authors:  Qing He; Kaiwen Xiao; Yuntian Chen; Banghua Liao; Hong Li; Kunjie Wang
Journal:  BMC Urol       Date:  2019-10-23       Impact factor: 2.264

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.